Double-digit organic revenue growth and margin expansion continued, with strong results in Diagnostics and India, improved cash flow, and leverage below 3x. Strategic options for the Indian business are under review, and midterm financial targets remain on track.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.